Biomapas appoints Xavier Duburcq to lead growth push

Biomapas has appointed Xavier Duburcq as Chief Executive Officer, replacing David Passov following a mutually agreed leadership transition.

Duburcq takes charge at the Lithuanian-headquartered life sciences services provider as it seeks to expand its footprint across Europe and beyond. Biomapas operates across clinical trials, pharmacovigilance, medical information, regulatory affairs and medical writing.

Passov stepped down after what Biomapas described as a successful period of development. During his tenure, the business acquired Delta PV, expanding its pharmacovigilance work, and strengthened its operating platform.

Carbyne Equity Partners, the majority shareholder, credited Passov with guiding the company through an important phase and welcomed Duburcq as the next stage begins.

Passov linked his departure to the progress made during his time in charge.

"It has been a privilege to lead Biomapas during such a meaningful phase of its journey. I leave with deep pride in our shared accomplishments and great confidence in Biomapas' continued success," said David Passov.

Growth plans

Biomapas now aims to build a diversified pharma services platform with revenue of more than €200 million, driven by a mix of organic expansion and acquisitions. It also plans to broaden its geographic reach and add scientific depth across its service lines.

Carbyne Equity Partners said Duburcq is well suited to that next phase, citing his track record of building teams in international settings.

"We sincerely thank David for his commitment and impact during a key transition period. We are delighted to welcome Xavier Duburcq as CEO. His leadership style, international experience, and ability to build strong, aligned organizations make him ideally suited to lead Biomapas forward," said Carbyne Equity Partners.

Duburcq joins a market where drug developers increasingly rely on specialist providers for clinical and regulatory work, as well as safety monitoring once products reach patients. The shift has created opportunities for groups that can offer multiple services under one roof, particularly across several European jurisdictions.

Biomapas works with customers ranging from emerging biotechnology companies to large pharmaceutical groups, and also serves medical device companies. The business positions itself around integrated services spanning development and post-marketing activity.

New leadership

Duburcq's mandate includes scaling operations across markets while maintaining service delivery as the company expands. Biomapas highlighted further investment in talent and greater use of digital tools as priorities for the next stage of growth.

In his first comments as CEO, Duburcq acknowledged the work completed under his predecessor and set out priorities for the period ahead.

"I am truly excited to join Biomapas at this important moment in its development. I would like to sincerely thank David for his leadership and for the strong foundation he has built. I look forward to working closely with our teams and clients to strengthen impact, foster innovation, scale our capabilities, and unlock the full potential of Biomapas across markets," said Xavier Duburcq, Chief Executive Officer, Biomapas.

Growth is expected to come from further expansion of existing services and targeted acquisitions, with Carbyne Equity Partners continuing to back the strategy.